chronic immune thrombocytopenic purpura
Haematology · 2009–2022
4decisions
3medicines
1carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| avatrombopag Treatment of severe thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) who have had an inadequate response or are… | Nov 2022 | Recommended with restriction | 8 individuals |
| romiplostim Treatment of severe thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are either splenectomised with… | Jul 2010 | Recommended with restriction | no section in document |
| eltrombopag olamine Adult patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) who have an inadequate response or are intolerant to corticosteroids and… | Nov 2010 | Recommended | no section in document |
| romiplostim Initial and continuing treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are either non-splenectomised with… | Jul 2009 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.